1) Has the FDA approval of adjuvant nivolumab impacted your practice volume? If so, can you estimate by how much. eg: 10% increase in volume
2) Compelling data supporting adjuvant BRAF/MEK was released at the same time. Though not yet FDA approved, I know many practices are already using.
Is your practice? IF so, has this too influenced your volume- and by how much?
Trying to get a sense of the overall impact of these incredible practice changing events (for providers).